A New Strategy of Cancer Immunotherapy Combining Hyperthermia/Oncolytic Virus Pretreatment with Specific Autologous Anti-Tumor Vaccination – A Review

Schirrmacher V*, Lorenzen D, Van Gool SW and Stuecker W
Immunological and Oncological Center Cologne (IOZK), Germany

*Corresponding author: Schirrmacher Volker, Immunological and Oncological Center Cologne (IOZK), Cologne, Germany

Received: February 02, 2017; Accepted: February 14, 2017; Published: February 17, 2017

Abstract

This review describes and explains a specific immunotherapy strategy that has been developed at the Immunological and Oncological Center Cologne in Germany. The strategy is based on many years of basic and translational research. It is a highly individualized approach to activate and target the patient’s immune system against the patient’s own tumor. In a first step, the patient’s immune system is conditioned by pretreatment with oncolytic virus in combination with hyperthermia. The second step consists of active-specific autologous anti-tumor vaccination. The vaccine, VOL-DC, consists of autologous Dendritic Cells (DCs) which are loaded with Viral Oncolysate (VOL) from the patient’s tumor cells. VOL transfers to the DCs information about tumor-associated antigens from the patient’s tumor and Pathogen-Associated Molecular Patterns (PAMPs, danger signals) from the virus. The product VOL-DC, which involves Newcastle Disease Virus, has been approved in Germany as an Advanced Therapeutic Medicinal Product for individual treatment by the institution which received this permit. This review includes promising results from case-series studies of glioblastoma patients. It also discusses future strategies for treatment of late-stage disease including combination of this immunotherapy with immune checkpoint blocking antibodies and/or with costimulatory bispecific antibodies.

Keywords: Cancer vaccine; Dendritic cell; Oncolytic virus; Newcastle disease virus; Immunogenic cell death; Memory T cell

Introduction

Immunotherapy of cancer holds promise for cancer patients as a new biological treatment procedure. In contrast to surgery, chemotherapy and radiotherapy - present-day standard therapies - which focus only on the tumor, immunotherapy is concerned with both, the tumor and the tumor-bearing host. Tumor-host interactions are particularly relevant in the fight against metastatic disease. Because the immune system is systemic it has the potential to protect against systemic disease such as metastasis.

Results of recent clinical studies involving novel immunotherapy strategies such as immune checkpoint blockade and adoptive T-cell transfer approaches have clearly established immunotherapy as an important modality for the treatment of cancer [1]. Immunotherapy can complement the traditional approaches of standard therapy or small molecule targeted therapy or it can be employed as monotherapy. To date, immunotherapy has been shown to be capable of inducing durable clinical benefit, although only in a fraction of the patients. The challenge, therefore, is how to increase the fraction of responding patients. It is generally accepted that the ultimate goal and read-out of immunotherapy is the increase in median Overall Survival (OS) and particularly in the percentage of patients with long-term survival. There is no doubt that this necessitates new strategies for personalization and combinatorial approaches [2,3].

A personalized immunotherapy approach is what the
Immunological and Oncological Center (IOZK) in Cologne, Germany, is aiming at. It has developed a treatment technology involving the patient’s tumor cells, the patient’s Dendritic Cells (DCs) and an Oncolytic Virus (OV) [4,5] to produce a vaccine called VOL-DC. VOL stands for Viral Oncolykate and the virus used is the bird virus Newcastle Disease Virus (NDV). Treatment of cancer patients by NDV oncolysate vaccines without DCs, performed in the 1970s, had already given interesting results [6,7] but for decades thereafter there had been only little interest in OVs. A revival of interest occurred luckily in the 2000s with more knowledge about OVs and new technologies, such as DC culture [8].

VOL-DC is a DC1 polarized vaccine which presents Tumor-Associated Antigens (TAAs) from the patient’s tumor to the patient’s T cells and activates the latter to TAA-specific T helper cells and Cytotoxic T Lymphocytes (CTLs). After several such vaccinations, the patient’s immune system is enriched with TAA-specific Memory T Cells (MTCs) which help to protect against possibly disseminated tumor cells and micro-metastases. It is this immunological memory which distinguishes immunotherapy from conventional therapies and provides a basis for improvements in long-term survival.

VOL-DC is a licensed Advanced Therapeutic Medicinal Product (ATMP) in Northern-Westfalia, Germany, and applied to patients at IOZK on a compassionate use basis.

**Immune modulation by hyperthermia/oncolytic virus pretreatment**

Active specific immunization of cancer patients requires an immune system which is competent and not dysregulated. Therefore, before patients at IOZK receive vaccinations, their immune system is assessed in depth. Immune modulation/conditioning of the immune system 1 week before vaccination is done by modulated Electrohyperthermia (mEHT) combined with systemic (i.v.) application of NDV [5].

**Modulated electrohyperthermia:** Hyperthermia with a tissue temperature of 38.5 to 40.5°C can activate the immune system [9,10]. mEHT is combined with systemic oncolytic NDV virotherapy based on the observations that mEHT can enhance virus tumor targeting [10] and virus replication [11]. mEHT is applied either locally or systemically, depending on the clinical situation. Viral infection of tumor cells and hyperthermia with a radiofrequency of 13 MHz cause an Endoplasmic Reticulum (ER) stress response, modify the surface properties of tumor cells and induce Immunogenic tumor Cell Death (ICD) mechanisms [4,5,12].

**Systemic NDV application:** It is the high safety profile which allows the avian paramyxovirus NDV to be applied to cancer patients [5]. The reported side effects after experience with clinical application for 50 years [7] are grade 1 and 2. Special characteristics of NDV include:

i) Lack of gene exchange via recombination,

ii) Lack of interaction with host cell DNA,

iii) Viral replication in the cytoplasm of cells being independent of host cell proliferation and

iv) Tumor selectivity of virus replication and of host cell lysis [5,7].

Identified mechanisms that can explain tumor selectivity of virus replication and oncolysis in tumor cells of non-permissive hosts such as man involve:

i) Defects in activation of anti-viral signaling pathways,

ii) Defects in type I IFN signaling pathways and

iii) Defects in apoptotic pathways [5].

Systemic NDV application has the following positive effects:

i) Induction of type I Interferons (IFNs) [13] which inhibit secretion of Th2 cytokines (IL-4 and IL-5), stimulate Th1 cells and counter-act Treg cells,

ii) Induction of ICD in virus-infected tumor cells [4,5,7,14] and

iii) Priming of NDV Viral Oncolykate (VOL) - reactive T cells which can be monitored by an *in vitro* ELISPOT assay [15].

Immune modulation prior to specific vaccination has a preconditioning effect on the patient’s immune system. The induction of VOL-reactive T cells will create systemic recall responses at the site of VOL-DC vaccination and thereby enhance DC migration to the draining lymph nodes with improved antitumor efficacy [16].

**Concept of the DC vaccine VOL-DC**

Tumorlysate-pulsed DCs as APCs for TAAs: Human TAAs were first described in the early 1990s. It formed the basis for a new era of molecularly defined tumor immunology. In the following years, numerous TAAs, either uniquely expressed or more common, have been characterized and respective HLA-restricted epitopes or neo-epitopes that are capable of triggering CD8+ and CD4+ T cell responses have been identified.

With the introduction of dendritic cell culture and the demonstration of DC’s T cell stimulatory capacity [8], methods have been developed to load DCs with TAAs or tumorlysate [17] and to use them as professional Antigen-Presenting Cells (APCs) for the *de novo* induction of TAA-specific T cell responses in cancer patients.

We decided to use autologous tumorlysate instead of defined TAAs to produce APCs based on the following findings:

1. Upon loading with crude tumor lysate proteins, human DCs cross-present CD8+ T cell epitopes in the context of MHC class I and present CD4+ T cell epitopes in the context of MHC class II. This was shown to be an active metabolic process leading to functional DCs able to induce TAA-specific CD8+ CTL activity [18].

2. Using a short-term IFN-γ ELISPOT assay, cancer-reactive MTCs from patient’s Bone Marrow (BM) were analyzed by stimulation with tumorlysate-pulsed DCs. Altogether, T cells reactive against the entirety of TAAs could be detected in about 40% of primary operated breast cancer patients. These existed at frequencies of 1:200 to 1:10,000 of total T cells and included CD8+ CTL and CD4+ Th cells [19].

3. The memory T-cell repertoire of the BM of primary operated breast cancer patients was analyzed in more detail and compared to that of healthy female donors. This was done by tumorlysate-pulsed
DCs and DCs pulsed with HLA-A2-peptides from 10 different breast TAAAs and a variety of normal breast tissue-associated antigens. The T-cell repertoire was highly polyvalent and exhibited pronounced inter-individual differences in the pattern of TAAs recognized by each patient [20].

4. In comparison to reactivity towards TAAs, reactivity to normal breast tissue-associated antigens was much lower. Healthy individuals also contained TAA-reactive T cells but this repertoire was more restricted and the frequencies were in the same low range as T cells reacting to normal breast tissue-associated antigens [20]. Since there was hardly a repertoire of MTCs reacting to normal tissue antigens, it does not seem necessary to purify single TAAs from tumor cells for vaccination purposes to avoid reactivity to tumor-derived normal tissue antigens.

Taken together, the analysis revealed that the BM appears as a lymphoid organ particularly involved in the induction and/or maintenance of natural T cell immunity against tumor antigens [19]. The spontaneous generation of cancer-reactive MTCs appears as a physiological process, also independent of TAA purification. The analyses involving tumourlysate-pulsed DCs revealed

i) That tumourlysate can serve as a source of TAAs,

ii) That tumourlysate-pulsed DCs as APCs do not induce autoimmune reactivity and

iii) That tumourlysate makes it unnecessary to purify TAAs.

Tumourlysate obtained from heat-stressed tumor cells was found to generate more potent DC vaccines than other antigen-loading strategies [21].

**Viral oncolysate for DC programming, polarization and TAA information transfer:** To create an effective DC vaccine it is important to avoid that the antigen-loaded cells induce tolerance instead of an immune response. DCs are not only activators but also modulators of immune responses. Depending on the context in which DCs interact with antigens they will affect T helper precursor cells in different ways, for instance to differentiate into Th1, Th2, Th17 or Treg.

To avoid a wrong polarization of T helper cells we decided to introduce so called “danger signals” into the DC vaccine by virus infection. Foreign viral non-capped RNA in the cytoplasm of a cell infected by an RNA virus is a Pathogen-Associated Molecular Pattern (PAMP) that stimulates innate immunity [5]. Thus, VOL-DCs consist of three components: autologous tumor cells as a source of tumor-characteristic TAAs, patient-derived DCs as professional APCs and the oncolytic virus NDV do deliver PAMPs. In addition, the emission of Damage-Associated Molecular Patterns (DAMPs) following ICD favors the establishment of a productive interface with the immune system [5,22]. Further features of NDV relate to the immune response:

i) Up-regulation of MHC I,

ii) Activation of NK cells,

iii) Activation of monocytes,

iv) Activation of DCs,

v) Costimulation of CD4+ and CD8+ T-cells [5].

This results in the elicitation of tumor-targeting immune responses associated with the potential to eliminate residual, treatment-resistant cancer cells and to establish tumor-reactive immunological memory.

NDV viral oncolysate (VOL) from autologous tumor cells is used to load patient-derived immature DCs. The material is taken up by macropinocytosis and processed along endogenous professional antigen-presentation pathways for generation of HLA-class II peptide complexes and along cross-presentation pathways to generate HLA-class I peptide complexes. VOL also contains viable NDV.

With the viral oncolysate the DCs receive information about the patient’s own tumor, in particular about its individually specific and common TAAs. The rationale for this autologous approach has been summarized [23]. New findings about the individuality of genetic and immunobiological changes in human tumor cells support this rationale. For instance, a dominance of mutation-derived unique tumor neo-antigens was described in an analysis of 598 human colorectal carcinomas indicating that cancer vaccination requires individualized strategies [24].

**Importance of NDV-induced signaling through RIG-I and type I interferon receptor:** The bird virus NDV induces in DCs and other normal cells from non-permissive hosts such as man a strong type I interferon response. This response which occurs within 18 hrs after infection consists of an early phase and a late phase [25].

The early phase is initiated through the recognition of viral RNA by two types of pathogen recognition receptors:

i) Endosomal Toll-Like Receptors (TLRs), particularly TLR3,7 and 8 and

ii) Cytoplasmic Retinoic acid Inducible Gene I (RIG-I) receptors. RIG-I binds specifically to RNA containing 3'-phosphate, such as viral RNA. Mammalian RNA is either capped or contains base modifications. RIG-I triggering involves the upregulation of RIG-I RNA copies. Once activated, RIG-I binds to the adaptor protein IFN-ß Promoter Stimulator-1 (IPS-1) which, after a further signaling cascade, activates the IFN regulatory factor IRF-3. This Transcription Factor (TF) is then phosphorylated, translocates to the nucleus and induces the IFN response [25].

During the late phase of the IFN response, the type I IFN molecules secreted during the early phase (IFN-α and IFN-ß) interact with the cell surface expressed α-chain of the type I Interferon Receptor (IFNRA). This initiates an amplification loop of the IFN response, which involves Signal Transducers and Activators of Transcription (STAT) proteins and the IFN regulatory factor IRF-7. Upon ligand binding, receptor associated Tyk2 and JAK1 become activated by transphosphorylation. These in turn phosphorylate STAT1 and STAT2. These STAT proteins then heterodimerize and form a complex with the IFN regulatory factor IRF-9 known as ISGF3. It translocates to the nucleus to bind to the IFN-Stimulated Response Element (ISRE) and directs the expression of IFN-Stimulated Genes (ISGs) that create the antiviral state in the target cells which blocks viral replication [25].

The effect of NDV on human DCs has been studied in a

---

*Submit your Manuscript | www.austinpublishinggroup.com*
very sophisticated way using technologies developed by systems biology [26]. NDV was considered a prototype avian virus to study an uninhibited cellular response to virus infection. The analysis revealed that the genetic program underlying the anti-viral cell-state transition during the first 18 h post-infection can be explained by a single convergent regulatory network involving 24 critical TFs. These factors regulated 779 of the 1351 up-regulated genes. Many of these genes were associated with polarization of the DCs towards DC1 and for induction of Th1 T-cell mediated immune responses.

Such programming and polarization of human DCs by NDV to DC1 was confirmed in functional studies [27].

Signaling through RIG-I and IFNRA plays an important role for immune activation by the avian virus NDV in man. They also play an important role for immune evasion by the primate virus Ebola. The latter does not induce type 1 IFN responses in man as it has viral proteins that specifically and strongly interfere with RIG-I and IFNRA signaling [28].

Preparation of VOL-DCs and functional tests

Preparation: In 2015, IOZK succeeded in producing NDV from cell culture at high titers and with high purity according to GMP guidelines. This is worldwide achieved for the first time. Also, the methodology to produce VOL-DC has meanwhile been established and quality certified as an ATMP at the IOZK in Germany.

Figure 1 illustrates the main features for the preparation of the three-component vaccine VOL-DC.

Functional tests: A study with memory T cells from breast cancer patients compared the stimulatory capacity of VOL-DCs to that of tumorlysate-pulsed DCs. Stimulation with VOL-DCs showed increased expression of costimulatory molecules and induced higher IFN-γ ELISPOT responses. Supernatants from co-cultures of MTCs and VOL-DCs contained increased titers of IFN-α and VOL-DCs [29].

The study revealed that VOL-DCs are superior to tumorlysate-pulsed DCs and potently stimulate MTCs from cancer patients.

Clinical studies

Pre-studies with ATV-NDV: The development of the three-component vaccine VOL-DC is an extension from the two-component vaccine ATV-NDV. This term stands for Autologous Tumor Vaccine modified by infection with NDV. The rationale for using autologous cancer vaccines is based on experience from animal tumor studies. Pre-clinical results from post-operative vaccination studies in mouse and guinea pig models of metastasizing cancers revealed that protective anti-tumor immunity could be induced by autologous but not allogeneic vaccines. The induced protective immunity was highly specific for the autologous tumor [23].

Table 1 lists examples of clinical vaccination trials employing the whole cell tumor vaccine ATV-NDV [30-36]. Here we want to comment only two of these studies. In Study 6, 23 patients suffering from GBM were vaccinated with ATV-NDV from cell culture to assess feasibility, safety and clinical benefit [35]. The median Overall Survival (OS) was 100 weeks (25 months) (versus 49 weeks (12 months) in control time period and the same clinic). The median Progression-Free Survival (PFS) of vaccinated patients was 40 weeks (versus 10 weeks in control group). The study revealed that protective anti-tumor immunity could be induced by autologous but not allogeneic vaccines. The induced protective immunity was highly specific for the autologous tumor [23].

Table 1: Clinical pre-studies with the vaccine ATV-NDV.

<table>
<thead>
<tr>
<th>Study-Disease</th>
<th>Study Type</th>
<th>Clinical Outcome</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Breast Ca (locally advanced)</td>
<td>Phase II (n = 32)</td>
<td>Improved OS and DFS</td>
<td>30</td>
</tr>
<tr>
<td>2. CRC (locally advanced) (stage II &amp; III)</td>
<td>Phase II (n = 57)</td>
<td>Improved OS and DFS</td>
<td>31</td>
</tr>
<tr>
<td>3. CRC (R0 resection) (stage IV)</td>
<td>Phase II (n = 23)</td>
<td>Improved OS and DFS</td>
<td>32</td>
</tr>
<tr>
<td>4. Pancreatic Ca (G3)</td>
<td>Phase II (n = 53)</td>
<td>Improved OS and DFS</td>
<td>33</td>
</tr>
<tr>
<td>5. Head and Neck Ca (stage III + IV)</td>
<td>Phase II (n = 18)</td>
<td>Improved OS and DFS</td>
<td>34</td>
</tr>
<tr>
<td>6. Glioblastoma multiforme (GBM)</td>
<td>Phase II (n = 23)</td>
<td>Improved OS and DFS</td>
<td>35</td>
</tr>
<tr>
<td></td>
<td>Phase III (n = 51)</td>
<td>Not significant</td>
<td>36</td>
</tr>
</tbody>
</table>

A prospective randomized-controlled study, stratified for:

Colon Ca (R0 resection) | Improved OS (p = 0.01) |
Rectum Ca (R0 resection) | Improved OS and DFS |

All studies were performed post-operatively in the adjuvant situation as prophylaxis against metastases; they were approved by local ethic committees. All autologous NDV virus modified tumor cell vaccines were applied intradermally.

CRC: Colorectal Carcinoma; DFS: Disease-Free Survival; OS: Overall Survival; PFS: Progression-Free Survival.

Table 1:

<table>
<thead>
<tr>
<th>Study-Disease</th>
<th>Study Type</th>
<th>Clinical Outcome</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Breast Ca (locally advanced)</td>
<td>Phase II (n = 32)</td>
<td>Improved OS and DFS</td>
<td>30</td>
</tr>
<tr>
<td>2. CRC (locally advanced) (stage II &amp; III)</td>
<td>Phase II (n = 57)</td>
<td>Improved OS and DFS</td>
<td>31</td>
</tr>
<tr>
<td>3. CRC (R0 resection) (stage IV)</td>
<td>Phase II (n = 23)</td>
<td>Improved OS and DFS</td>
<td>32</td>
</tr>
<tr>
<td>4. Pancreatic Ca (G3)</td>
<td>Phase II (n = 53)</td>
<td>Improved OS and DFS</td>
<td>33</td>
</tr>
<tr>
<td>5. Head and Neck Ca (stage III + IV)</td>
<td>Phase II (n = 18)</td>
<td>Improved OS and DFS</td>
<td>34</td>
</tr>
<tr>
<td>6. Glioblastoma multiforme (GBM)</td>
<td>Phase II (n = 23)</td>
<td>Improved OS and DFS</td>
<td>35</td>
</tr>
<tr>
<td></td>
<td>Phase III (n = 51)</td>
<td>Not significant</td>
<td>36</td>
</tr>
</tbody>
</table>

A prospective randomized-controlled study, stratified for:

Colon Ca (R0 resection) | Improved OS (p = 0.01) |
Rectum Ca (R0 resection) | Improved OS and DFS |

All studies were performed post-operatively in the adjuvant situation as prophylaxis against metastases; they were approved by local ethic committees. All autologous NDV virus modified tumor cell vaccines were applied intradermally. CRC: Colorectal Carcinoma; DFS: Disease-Free Survival; OS: Overall Survival; PFS: Progression-Free Survival.

Functional tests: A study with memory T cells from breast cancer patients compared the stimulatory capacity of VOL-DCs to that of tumorlysate-pulsed DCs. Stimulation with VOL-DCs showed increased expression of costimulatory molecules and induced higher IFN-γ ELISPOT responses. Supernatants from co-cultures of MTCs and VOL-DCs contained increased titers of IFN-α and IL-15 [29].

The study revealed that VOL-DCs are superior to tumorlysate-pulsed DCs and potently stimulate MTCs from cancer patients.

Clinical studies

Pre-studies with ATV-NDV: The development of the three-component vaccine VOL-DC is an extension from the two-component vaccine ATV-NDV. This term stands for Autologous Tumor Vaccine modified by infection with NDV. The rationale for using autologous cancer vaccines is based on experience from animal tumor studies. Pre-clinical results from post-operative vaccination studies in mouse and guinea pig models of metastasizing cancers revealed that protective anti-tumor immunity could be induced by autologous but not allogeneic vaccines. The induced protective immunity was highly specific for the autologous tumor [23].

Table 1 lists examples of clinical vaccination trials employing the whole cell tumor vaccine ATV-NDV [30-36]. Here we want to comment only two of these studies. In Study 6, 23 patients suffering from GBM were vaccinated with ATV-NDV from cell culture to assess feasibility, safety and clinical benefit [35]. The median Overall Survival (OS) was 100 weeks (25 months) (versus 49 weeks (12 months) in control time period and the same clinic). The median Progression-Free Survival (PFS) of vaccinated patients was 40 weeks (versus 10 weeks in control group). The study revealed that protective anti-tumor immunity could be induced by autologous but not allogeneic vaccines. The induced protective immunity was highly specific for the autologous tumor [23].

Table 1:

<table>
<thead>
<tr>
<th>Study-Disease</th>
<th>Study Type</th>
<th>Clinical Outcome</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Breast Ca (locally advanced)</td>
<td>Phase II (n = 32)</td>
<td>Improved OS and DFS</td>
<td>30</td>
</tr>
<tr>
<td>2. CRC (locally advanced) (stage II &amp; III)</td>
<td>Phase II (n = 57)</td>
<td>Improved OS and DFS</td>
<td>31</td>
</tr>
<tr>
<td>3. CRC (R0 resection) (stage IV)</td>
<td>Phase II (n = 23)</td>
<td>Improved OS and DFS</td>
<td>32</td>
</tr>
<tr>
<td>4. Pancreatic Ca (G3)</td>
<td>Phase II (n = 53)</td>
<td>Improved OS and DFS</td>
<td>33</td>
</tr>
<tr>
<td>5. Head and Neck Ca (stage III + IV)</td>
<td>Phase II (n = 18)</td>
<td>Improved OS and DFS</td>
<td>34</td>
</tr>
<tr>
<td>6. Glioblastoma multiforme (GBM)</td>
<td>Phase II (n = 23)</td>
<td>Improved OS and DFS</td>
<td>35</td>
</tr>
<tr>
<td></td>
<td>Phase III (n = 51)</td>
<td>Not significant</td>
<td>36</td>
</tr>
</tbody>
</table>

A prospective randomized-controlled study, stratified for:

Colon Ca (R0 resection) | Improved OS (p = 0.01) |
Rectum Ca (R0 resection) | Improved OS and DFS |

All studies were performed post-operatively in the adjuvant situation as prophylaxis against metastases; they were approved by local ethic committees. All autologous NDV virus modified tumor cell vaccines were applied intradermally. CRC: Colorectal Carcinoma; DFS: Disease-Free Survival; OS: Overall Survival; PFS: Progression-Free Survival.

Functional tests: A study with memory T cells from breast cancer patients compared the stimulatory capacity of VOL-DCs to that of tumorlysate-pulsed DCs. Stimulation with VOL-DCs showed increased expression of costimulatory molecules and induced higher IFN-γ ELISPOT responses. Supernatants from co-cultures of MTCs and VOL-DCs contained increased titers of IFN-α and IL-15 [29].

The study revealed that VOL-DCs are superior to tumorlysate-pulsed DCs and potently stimulate MTCs from cancer patients.

Clinical studies

Pre-studies with ATV-NDV: The development of the three-component vaccine VOL-DC is an extension from the two-component vaccine ATV-NDV. This term stands for Autologous Tumor Vaccine modified by infection with NDV. The rationale for using autologous cancer vaccines is based on experience from animal tumor studies. Pre-clinical results from post-operative vaccination studies in mouse and guinea pig models of metastasizing cancers revealed that protective anti-tumor immunity could be induced by autologous but not allogeneic vaccines. The induced protective immunity was highly specific for the autologous tumor [23].

Table 1 lists examples of clinical vaccination trials employing the whole cell tumor vaccine ATV-NDV [30-36]. Here we want to comment only two of these studies. In Study 6, 23 patients suffering from GBM were vaccinated with ATV-NDV from cell culture to assess feasibility, safety and clinical benefit [35]. The median Overall Survival (OS) was 100 weeks (25 months) (versus 49 weeks (12 months) in control subjects; p<0.001). In the vaccinated group, immune monitoring revealed significant increases of skin DTH reactivity, of the number of tumor-reactive MTCs in the blood and of the number of CD8+ Tumor-Infiltrating T-cells (TILs) in frozen tissue slices from GBM recurrences. There was one complete remission of non-recteable remaining tumor [35].
Study 7 (Table 1), a prospectively randomized Phase II/III trial, investigated the efficiency of ATV-NDV after liver resection for hepatic metastases of Colorectal Carcinoma (CRC) as a tertiary prevention method [36]. 25 of such stage IV CRC patients were vaccinated and compared with a similar number of non-vaccinated otherwise comparable patients. After an exceptionally long follow-up period of 9 to 10 years, there was no significant difference between the vaccinated and the control arm when comparing all patients. However, when stratified for tumor location, there were significant differences between colon and rectum. While there was no significant difference for rectal cancer, a significant benefit was seen in the colon cancer subgroup in terms of long-term metastasis-free survival and OS. In the control arm, 78.6% had died, in the vaccinated arm only 30.8% [36].

The trial is a good example of Evidence Based Medicine. It provides clinical evidence for the value and potential of the cancer vaccine ATV-NDV.

New results from case series studies with VOL-DC at IOZK: IOZK exists since more than 10 years as a private praxis in Cologne. During this time more than 1200 cancer patients were treated with biological therapies. Among them were more than 70 different types of cancer. Since this treatment is highly individual the results can only be evaluated as single case or as case-series studies. Two remarkable single cases were recently published. One describes long-term remission of prostate cancer with extensive bone metastases [37], the other reports long-term survival of a breast cancer patient with extensive liver metastases [15].

Now we summarize new results from a retrospective case-series of GBM patients treated at IOZK between 2006 and 2010. Figure 2 shows the results of a Kaplan-Meier survival analysis of 10 newly diagnosed GBM patients in comparison to standard radio/chemotherapy. These data derive from patients treated before the time of the GMP certificate.

The trial is a good example of Evidence Based Medicine. It provides clinical evidence for the value and potential of the cancer vaccine ATV-NDV.

Future phase II/III clinical study design from deltavir

Delta-Vir GmbH is a start-up company from IOZK at the BIOCITY Leipzig (Germany). Its aim is to expand the immunotherapy developed at IOZK and to evaluate the treatment concept in clinical studies. Deltavir has produced a dossier for the European Medicines Agency (EMA) which was accepted by the Scientific Advice Procedure. Deltavirs product for the treatment of GBM has also been presented to the Committee for Orphan Medical Products (COMP).
Figure 3 illustrates the study design for a randomized 2 arm study of GBM comparing standard therapy against standard treatment plus treatment with NDV and VOL-DC. The primary endpoint is OS after 2 years and the secondary endpoints are PFS and quality of life.

Counteracting tumor-induced resistance

Breaking tumor resistance by oncolytic NDV: Many characteristics of oncolytic NDV suggest that this biological agent has the potential to break resistance of cancer cells to a variety of therapies. Some of these are summarized in Table 2. Since this virus replicates in the cytoplasm of tumor cells, it is independent of DNA replication. The virus replicates perfectly well in X-irradiated tumor cells, for instance in cells of the vaccine ATV-NDV. Many tumor cells in a resting state such as tumor stem cells or cells from tumor dormancy are not affected by chemo- or radio-therapy, but are still targeted by oncolytic NDV.

Of special interest are also recent findings demonstrating that oncolytic NDV selectively infects apoptosis-resistant [39], hypoxic [40] or type I interferon-resistant tumor cells [25]. This oncolytic virus could therefore very well complement conventional therapies which lack these properties. NDV seems particularly suited to treat GBM tumors. GBM is characterized by Rac1 protein expression and aberrant signaling which facilitates tumor cell motility and invasion. It is exactly this Rac1 protein which is targeted by NDV infection [41].

NDV may even break resistance mechanisms to immunotherapy. T-cell tolerance (non-responsiveness) to melanoma-associated TAA could be overcome by melanoma cell infection with NDV [42]. Furthermore, localized oncolytic virotherapy with NDV was demonstrated to overcome even systemic tumor resistance to immune checkpoint blockade [43].

These findings suggest combining hyperthermia/NDV pre-treatment and VOL-DC with immune checkpoint blocking antibodies. The former procedure induces TILs and the latter prevents negative influences from tumor cells against the TILs.

Increasing T cell costimulatory signals: T cell costimulation (via signal 2) is necessary to induce a response of naïve T cells. When costimulatory signals are lacking, for instance on a TAA-presenting tumor cell, interactions with TAA-specific T cells (signal 1 only) render the T cell anergic: the T cell becomes refractory to signals even when the antigen-specific T-cell receptor interacts with TAA. This situation has been described in cancer patients, especially in chronic situations of advanced disease [44]. T cell anergy [45] may exist in different states, not all of them being irreversible. For instance, tumor-reactive MTCs from draining lymph nodes of carcinoma patients could be re-activated in a short-term ELISPOT assay using as vaccine ATV-NDV with optimized signals 1 and 2, but not with a similarly modified vaccine from an unrelated tumor cell line [46].

We selected the viral Hemagglutinin-Neuraminidase (HN) protein of NDV as a universal anchor molecule of a vaccine to attach costimulatory molecules. This has the advantage that any NDV-infected tumor vaccine could be further modified by such HN binding costimulatory molecules. The design and production of a bispecific single-chain anti-HN-anti-CD28 fusion protein (bsHN-CD28) which can easily attach to the vaccine ATV-NDV has been described [47].

Whether strong T cell costimulation can cause re-activation of unreactive, possibly anergized memory T cells from late-stage cancer patients has been investigated in CRC patients [48]. 14 CRC patients with late-stage disease which could not be operated anymore with curative intent were treated with the newly modified vaccine ATV-NDV-bsHN-CD28. No severe adverse events were observed. While before vaccination, none of the patients showed immunological responsiveness of blood-derived T cells in ELISPOT assays, after vaccinations all patients showed an immunological response of blood-derived T cells, at least once during the course of five vaccinations.

Also, we demonstrated a dose-response relationship with the purified costimulatory molecule bsHN-CD28 when added to the vaccine. Within the first 3 days after the first vaccination there was a strong and significant increasing of blood-circulatory TAA-peptide-specific T cells. Such responses were observed in ELISPOT assays to DCs pulsed either with autologous tumourlysate or with 20mer peptides from defined common TAAAs such as p53, CEA, Her-2/ neu and Mage-3 [48]. A partial response (>30% decrease, RECIST criteria) of metastases was documented in four patients.

The study suggests that the three-component vaccine is safe and can re-activate possibly anergized T cells in advanced-stage cancer [48].

Summary and conclusions

This review is based on more than three decades of pre-clinical and translational research. The overall goal is a contribution to establishing immunotherapy as a new standard treatment of cancer. Although this may still be a long way to go, it will be to the benefit of cancer patients. This conviction is based on the fact that the immune system functions in a systemic way, is capable of distinguishing tumor from normal tissue and is equipped with a specific memory function.

Following a description of our rationale, we present results from clinical studies. These include pre-studies with the autologous virus-modified tumor cell vaccine ATV-NDV, developed and tested in Heidelberg, Germany, as well as new results from case-series studies with the three-component dendritic cell vaccine VOL-DC, developed and tested in Cologne, Germany.

The experience obtained at IOZK with the described combinatorial immunotherapy involving hyperthermia, oncolytic virus and autologous VOL-DC vaccines is promising. There were surprising responses in cases in which conventional therapies had failed. The evaluation of the case-series from GBM suggests clear-cut prolongation of median OS. Of further importance is that the immunotherapy is well tolerated and does not have a negative impact on the patient’s life style.

Concerning future developments, we propose two further strategies:

i) To combine such immunotherapy with procedures to counteract tumor-induced breaks and

ii) To provide additional T-cell co-stimulatory signals to overcome T-cell anergy. Immune checkpoint blockade will reduce negative signals while costimulation will provide positive signals to TILs. The outcome in the tumor microenvironment will likely depend on the ratio of positive to negative signals. Both strategies
appear relevant, in particular in stages of late-stage disease in which other types of therapies have failed.

References

7. Schirmacher V. Fifty Years of Clinical Application of Newcastle Disease Virus: Time to celebrate! Biomedicines. 2016.


